Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 15 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 12 13 14 15 presentations: 1 to 25 of 366
Computational Cancer Epigenomics
Genome-scale analysis of DNA methylation in cancer: Discoveries, challenges, and opportunities
Hui Shen
Van Andel Research Inst., Grand Rapids, MI, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Computational Cancer Epigenomics
Prioritizing non-coding variants in cancer genomes using epigenetic profiles
Peter J. Park
Harvard Medical School, Boston, MA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Computational Cancer Epigenomics
Modeling cancer gene regulation with public ChIP-seq profiles
X Shirley Liu
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Alterations and Inhibition of the Spliceosome
Basic mechanisms of splicing catalysis and regulation
Clara L Kielkopf
University of Rochester Medical Center, Rochester, NY, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Alterations and Inhibition of the Spliceosome
Genetics and biological studies of spliceosomal mutations in cancer
Matthew Walter
Washington University, Saint Louis, MO, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Alterations and Inhibition of the Spliceosome
Understanding and targeting SF3B1 in cancer
Silvia Buonamici
H3 Biomedicine, Boston, MA, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Alterations and Inhibition of the Spliceosome
The role of splicing regulatory proteins in cancer
Omar I Abdel-Wahab
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Stem Cells in Cancer
Leukemic stem cells lie at the origin of AML relapse
John E. Dick
Univ. of Toronto, Toronto, ON, Canada
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Stem Cells in Cancer
Niche and metastasis intiation
Ilaria Malanchi
Cancer Research UK, London, United Kingdom
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Stem Cells in Cancer
Repopulation of cancer stem cells in therapeutic resistance
Keith S. Chan
Baylor College of Medicine, Houston, TX, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Stem Cells in Cancer
Mammary stem cells and breast cancer
Rama Khokha
Univ. of Toronto Ontario Cancer Inst., Toronto, ON, Canada
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Measurable Residual Disease Testing in the Hematological Malignancies
Introduction to measurable residual disease in the hematological malignancies
Christopher S. Hourigan
NHLBI, Bethesda, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Measurable Residual Disease Testing in the Hematological Malignancies
Next-generation sequencing in the lymphoid malignancies
Aaron Logan
UCSF, San Francisco, CA, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Measurable Residual Disease Testing in the Hematological Malignancies
Flow cytometry in the myeloid malignancies
Roland B Walter
Fred Hutchinson Cancer Research Center, Seattle, WA, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Measurable Residual Disease Testing in the Hematological Malignancies
Regulatory aspects of MRD in clinical trials
Nicole J Gormley
U.S. Food and Drug Administration, Silver Spring, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
The Pediatric Cancer Genome
Acute lymphoblastic leukemia
Charles G. Mullighan
St. Jude Children's Research Hospital, Memphis, TN, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
The Pediatric Cancer Genome
Credentialing genomic medicine in pediatric oncology: Neuroblastoma as a model
Yael P. Mosse
Children's Hospital of Philadelphia, Philadelphia, PA, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
The Pediatric Cancer Genome
Pediatric and adult high grade gliomas: A tale of a histone tail
Nada Jabado
McGill University Department of Pediatrics, Montreal, QC, Canada
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Epigenetic Therapies: From Bench to Bedside in Acute Myeloid Leukemia
Invited speaker
Mark Dawson
Peter MacCallum Cancer Center, Victoria, Australia
from AACR Annual Meeting 2016 on April 17, 2016 7:00 AM-8:00 AM
Making the Most of Single Cell RNA-Seq Data
Invited speaker
Dana Pe'er
Columbia University, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 7:00 AM-8:00 AM
Multiple Myeloma
The impact of genomics on diagnosis, prognosis, and treatment of myeloma
Faith Davies
University of Arkansas for Medical Sciences, Little Rock, AR, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:00 PM
Multiple Myeloma
The importance of plasma cell biology in treating newly diagnosed multiple myeloma
Sagar Lonial
Emory University Winship Cancer Institute, Atlanta, GA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:00 PM
Multiple Myeloma
Treatment of relapsed myeloma with novel targeted and immune therapies
Kenneth C. Anderson
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:00 PM
New Drugs on the Horizon 1
Co-Chairperson
Indrawan J. Mcalpine
Pfizer Global R&D, San Diego, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
New Drugs on the Horizon 1
Discovery and pre-clinical pharmacology of AZD0156: A first-in-class potent and selective inhibitor of Ataxia telangiectasia mutated (ATM) kinase
Elaine Cadogan
AstraZeneca, Cambridge, United Kingdom
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
<< first | < prev page: of 15 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 12 13 14 15 presentations: 1 to 25 of 366